Pan Cancer T
Rotterdam
About Pan Cancer T
Pan Cancer T is a biotechnology company that develops T-cell receptor T-cell therapies to treat solid tumors. The company’s lead therapy candidate, PCT1:CO-STIM, is engineered to recognize a tumor-restricted antigen called ROPN1, a target expressed in over 90% of cases of certain cancers such as triple-negative breast cancer (TNBC) and melanoma. The therapy also incorporates a proprietary co-stimulatory engineering design meant to overcome immune resistance often present in solid tumors, thereby improving T cell durability and response potential even in hostile tumor microenvironments. Pan Cancer T’s pipeline extends beyond TNBC. The company is developing TCR-T therapies for a broad range of solid cancers, including cancers of the bladder, ovary, colorectum, prostate, skin, oesophagus, lung, and brain.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $16.3M
- Funding stage: Seed
- Last round: Seed (Dec 2025)
- Website: pancancer-t.com
Industries & Categories
Biotechnology, Life Science, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/pan-cancer-t-76009 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.